Geldanamycin compounds and method of use

Details Geldanamycin compounds and method of use Geldanamycin compounds and method of use

2007-08-21

2007-08-21

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S461000

Reexamination Certificate

active

11133880

ABSTRACT:
Geldanamycin compounds having a structure according to formula Iwhere Q1, L, L1, R5, R6, and R11are as defined herein, are useful for treating a disease or disorder ameliorated by inhibiting the function of extracellular heat shock protein-90.

REFERENCES:
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 5510118 (1996-04-01), Bosch et al.
patent: 5534270 (1996-07-01), De Castro
patent: 5662883 (1997-09-01), Bagchi et al.
patent: 5932566 (1999-08-01), Schnur et al.
patent: 6015659 (2000-01-01), Welch et al.
patent: 6174875 (2001-01-01), DeFranco et al.
patent: 6670348 (2003-12-01), Rosen et al.
patent: 6855705 (2005-02-01), Tian et al.
patent: 6870049 (2005-03-01), Tian et al.
patent: 6875863 (2005-04-01), Tian et al.
patent: 6887993 (2005-05-01), Tian et al.
patent: 2002/0045570 (2002-04-01), Rosen et al.
patent: 2002/0077279 (2002-06-01), Kumar et al.
patent: 2003/0114450 (2003-06-01), Santi et al.
patent: 2004/0053909 (2004-03-01), Snader et al.
patent: 2005/0026894 (2005-02-01), Tian et al.
patent: 55-111419 (1980-08-01), None
patent: 55-111470 (1980-08-01), None
patent: 63-218620 (1988-09-01), None
patent: 04-046120 (1992-02-01), None
patent: WO94/08578 (1994-04-01), None
patent: WO 00/03737 (2000-01-01), None
patent: WO 02/36574 (2002-05-01), None
patent: WO 02/079167 (2002-10-01), None
patent: WO 03/066005 (2003-08-01), None
An et al.,Cancer Chemother. Pharmacol. 1997, 40, 60-64, “Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity.”
Carreras et al.,Anal. Biochem. 2003, 317, 40-46, “Filter binding assay for the geldanamycin-heat shock protein interaction”.
Cheng et al.,J. Med. Chem. 2005, 48, 645-652, “Synthesis and Enzyme-Specific Activation of Carbohydrate-Geldanamycin Conjugates with Potent Anticancer Activity”.
Clevenger et al.,J. Org. Chem. 69, 4375-4380 (2004), “Biotinylated Geldanamycin”.
Eustace et al.,Nature Cell Biology, 6 (6), 507-514 (2004, web-published May 16, 2004), “Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness”.
Ferrarini et al.,Int. J. Cancer, 1992, 613-619, “Unusual expression and localization of heat-shock proteins in human tumor cells” (abstract).
Hegmans et al.,Am. J. Pathol., 164 (5), 1807-15 (2004), “Proteomic Analysis of Exosomes Secreted by Human Mesothelioma Cells” (abstract).
Hickey et al.,Mol. Cell Biol. 1989, 9, 2615-2626, “Sequence and Regulations of a Gene Encoding a Human 89-Kilodalton Heat Shock Protein”.
Jez et al.,Chemistry&Biology, 10, 361-368 (2003), “Crystal Structure and Molecular Modeling of 17-DMAG in Complex with Human HSP90”.
López-Ortín et al.,Nature Rev. Mol. Cell Biol., 3, 509-519 (2002), “Protease Degradonomics: a New Challenge for Proteomics”.
Omura et al.,J. Antibiotics1984, 37 (10), 1264-1267, Chemical Modification and Antitumor Activity of Herbimycin A, 8-9-Epoxide, 7-9-Cyclic Carbamate, and 17- or 19-Amino Derivatives.
Pratt,J. Biol. Chem., 268 (29), 21455-21458 (1993), “The Role of Heat Shock Proteins in Regulating the Function, Folding, and Trafficking of the Glucocorticoid Receptor*”.
Schnur et al.,J. Med. Chem., 38, 3806-3812 (1995), “Inhibition of the Oncogene Product p185erbB-2in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives”.
Schnur et al.,J. Med. Chem., 38, 3813-3820 (1995), “erbB-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure-Activity Relationships”.
Sreedhar et al.,FEBS Letters562 (1-3), 11-15 (2004), “HSP90 Isoforms: functions, expression and clinical importance”.
Tian et al.,Bioorg. Med. Chem., 2004, 12, 5317-5329, “Synthesis and Biological Activities of Novel 17-Amino-geldanamycin Derivatives”.
Xu et al.,Proc. Natl. Acad. Sci(USA), 90, 7074-7078 (1993), “Heat-shock protein hsp90 governs the activity of pp60v-srckinase”.
Xu et al.,Proc. Natl. Acad. Sci. (USA), 96, 109-114 1999), “Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90”.

Affiliated with

Also associated with

Rating

Geldanamycin compounds and method of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Geldanamycin compounds and method of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Geldanamycin compounds and method of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3868279